Paper54209
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.
Bonadonna G and 4 others. Cancer, 1975. Cited by 638 papers, by iCite.
Cite this record
ConductScience Library. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Papers, record 54209. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/54209
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hodgkin Disease | Major topic |
| Adolescent | |
| Adult | |
| Bleomycin | |
| Child | |
| Doxorubicin | |
| Drug Therapy, Combination | |
| Drug Tolerance | |
| Female | |
| Humans | |
| Imidazoles | |
| Male | |
| Mechlorethamine | |
| Middle Aged | |
| Prednisone | |
| Procarbazine | |
| Prospective Studies | |
| Vinblastine | |
| Vincristine |
Source PubMed
Cited by128
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 638 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42358815 | Prognostic Value of Spatial and Topological Features of Tumor Microenvironment in Classic Hodgkin Lymphoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42358815 | PubMed |
| 42352453 | Systemic Therapy for Advanced-Stage Hodgkin Lymphoma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42352453 | PubMed |
| 42166512 | Advanced Stage Hodgkin Lymphoma: A Review on Frontline Treatment Advances. | Cancer J | 2026 | https://conductscience.org/library/papers/42166512 | PubMed |
| 41790282 | Evolution of outcomes in autologous stem cell transplantation for hodgkin lymphoma over 2 decades at King Hussein cancer center. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41790282 | PubMed |
| 41449752 | The importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma. | Br J Haematol | 2026 | https://conductscience.org/library/papers/41449752 | PubMed |
| 41256864 | Expression and prognostic value of FKBP51 in Hodgkin lymphoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/41256864 | PubMed |
| 41181846 | The national and subnational burden of Hodgkin Lymphoma (HL) in Italy from 1990 to 2023: results from the Global Burden of Disease Study 2023. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/41181846 | PubMed |
| 41063706 | Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience. | Haematologica | 2026 | https://conductscience.org/library/papers/41063706 | PubMed |
| 39202553 | The Effect of Diagnostic and Therapeutic Changes on the Survival of Hodgkin's Lymphoma Patients (1980-2019). | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39202553 | PubMed |
| 39034771 | Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305). | Cancer Sci | 2024 | https://conductscience.org/library/papers/39034771 | PubMed |
| 38893177 | Treatment Strategies in Advanced-Stage Hodgkin Lymphoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38893177 | PubMed |
| 38791909 | Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38791909 | PubMed |
| 38359378 | Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38359378 | PubMed |
| 37796339 | Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma. | Ann Hematol | 2024 | https://conductscience.org/library/papers/37796339 | PubMed |
| 37685994 | Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37685994 | PubMed |
| 37565112 | A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors. | Cureus | 2023 | https://conductscience.org/library/papers/37565112 | PubMed |
| 37459116 | Evaluating Alkaline Phosphatase-Instructed Self-Assembly of d-Peptides for Selectively Inhibiting Ovarian Cancer Cells. | J Med Chem | 2023 | https://conductscience.org/library/papers/37459116 | PubMed |
| 37361649 | Isolated Hodgkin lymphoma of the intracranial dura: A case report and review of the literature. | Clin Case Rep | 2023 | https://conductscience.org/library/papers/37361649 | PubMed |
| 36941843 | A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma. | Leuk Res Rep | 2023 | https://conductscience.org/library/papers/36941843 | PubMed |
| 36654739 | Genetic lesions and targeted therapy in Hodgkin lymphoma. | Ther Adv Hematol | 2023 | https://conductscience.org/library/papers/36654739 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/54209
GET https://conductscience.org/api/papers/v1/54209/cited_by?page=2